Introduction {#S1}
============

Rheumatoid arthritis (RA) is a chronic disease that is characterized by synovitis and damage of both cartilage and bone in synovial joints, leading to functional disabilities that affect up to 1% of the population worldwide ([@B1], [@B2]). The current generation of biological drugs are inhibiting inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, and IL-1, depleting B cells by targeting cluster of differentiation (CD) 20 or by inhibiting the co-stimulation of T cells by antigen-presenting cells ([@B3]). Although biologicals have increased the treatment efficacy of RA patients, a substantial percentage of RA patients do not respond or are refractory to current treatment. Furthermore, side effects of biologicals are increased risk of infections and the development of other autoimmune diseases ([@B4]). Restoring homeostasis by for example the administration of the anti-inflammatory cytokine IL-10 has shown little efficacy in clinical trials either due to counteractive effects or poor pharmacokinetics of this protein ([@B5], [@B6]). Activation of natural negative feedback mechanisms as a potential therapy for RA has not been fully explored.

The TAM receptors---TYRO3, AXL, and MER (gene name *MERTK*)---are receptor tyrosine kinases that play a critical role in natural anti-inflammatory feedback mechanisms. The two principal TAM receptor protein ligands are growth arrest-specific 6 (GAS6) and Protein S (PROS1). Notably, GAS6 is a ligand for all three receptors but with the highest affinity for AXL. In contrast, PROS1 can only activate TYRO3 and MER, but not AXL ([@B7]). These ligands display divalent binding activities: they bind to TAM receptors through a carboxy-terminal domain, and also, *via* an amino-terminal domain, to phosphatidylserine (PS) that is expressed as an "eat-me signal" on the surface of apoptotic cells ([@B7]). PROS1/GAS6 binding to PS effectively opsonizes apoptotic cells for TAM receptor-mediated phagocytic uptake, a process called efferocytosis ([@B8], [@B9]). Additionally, the TAM receptors negatively regulate inflammation, among others by inducing Suppressor Of Cytokine Signaling (SOCS) proteins 1 and 3 ([@B10]--[@B16]). SOCS1 and 3 inhibit TLR- and cytokine receptor signaling, resulting in reduced production of pro-inflammatory cytokines ([@B10], [@B16], [@B17]). The TAM receptors can also be shed from the cell surface thereby creating a soluble ectodomain. For MER, the enzyme responsible for this shedding is A Disintegrin AND Metallopeptidase Domain 17 (ADAM17) ([@B18]). By competing for the ligands with the membrane-bound MER, soluble MER has been shown to inhibit efferocytosis ([@B19]--[@B21]).

TAM receptors have been associated with numerous inflammatory diseases, such as multiple sclerosis, atherosclerosis, and various rheumatic diseases ([@B22]--[@B26]). These studies focused mainly on the association of the soluble ectodomains of the TAM receptors with disease activity parameters. We have previously shown that both systemic and intra-articular adenoviral overexpression of *Gas6* and *Pros1* in collagen-induced arthritis (CIA) reduces inflammation and bone and cartilage erosion in murine knee joints ([@B16]). The objective of this study was to illuminate the endogenous role of the MER tyrosine kinase, and its role upon PROS1 stimulation, in two different experimental models of arthritis and a three-dimensional model of the human synovium.

Materials and Methods {#S2}
=====================

Antibodies {#S2-1}
----------

The list of antibodies, origin, and function are given in Table [1](#T1){ref-type="table"}.

###### 

List of antibodies, origin, and function.

  Antibody                    Reactivity   Company            Catalog number   Monoclonal/polyclonal    Function               Figure (F)/Supplementary Figure (SF)
  --------------------------- ------------ ------------------ ---------------- ------------------------ ---------------------- --------------------------------------
  MER                         Human        Abcam              ab52968          Monoclonal \[Y323\]      Immunohistochemistry   F3A
  IgG for MER                 --           DAKO               X0936            --                       Immunohistochemistry   F3A
  CD68                        Human        DAKO               M0814            Monoclonal \[KP1\]       Immunohistochemistry   F3A
  IgG for CD68                --           DAKO               X0931            --                       Immunohistochemistry   F3A
  Secondary antibody          Mouse        DAKO               P0260            Polyclonal               Immunohistochemistry   F3A
  MER                         Human        Abcam              ab176887         Monoclonal \[Y323\]      Neutralization         F3BSF3A,B,C
  IgG for MER                 --           Abcam              ab176094         --                       Neutralization         F3BSF3A,B,C
  MER                         Mouse        R&D systems        AF591            Polyclonal               Activation             F4F5A,BF6A,B,C,DSF4, SF5
  IgG for MER                 --           R&D systems        AB-108-C         --                       Activation             F4F5A,BF6A,B,C,DSF4, SF5
  MER                         Mouse        R&D systems        AF591            Polyclonal               Immunoprecipitation    F4A
  MER                         Mouse        R&D systems        AF591            Polyclonal               Immunoblotting         F4A
  Phosphorylation             Mouse        Millipore          05-321           Monoclonal \[4G10\]      Immunoblotting         F4A
  Cleaved Caspase-3           Mouse        BD Pharmingen      559565           Monoclonal \[C92-605\]   Immunohistochemistry   F5
  IgG for Cleaved Caspase-3   --           DAKO               X0936            --                       Immunohistochemistry   F5
  MER                         Mouse        eBioscience        12-5751          Monoclonal \[DS5MMER\]   Flow cytometry         SF1A
  F4/80                       Mouse        Bio-Rad            MCA497           Monoclonal \[Cl:A3-1\]   Immunofluorescence     F6ASF5A
  Secondary antibody          Rat          Molecular probes   A11006           Polyclonal               Immunofluorescence     F6ASF5A

*In Vivo*  {#S2-2}
----------

### Mice {#S2-2-1}

Male DBA/1 (Janvier) were used for the CIA model and housed in filter top cages. Male C57BL/6 mice (Janvier) were used for KRN serum transfer arthritis (STA) experiments using viral overexpression in knee joints. Mice were housed in individually ventilated cages. Both mouse strains were used at an age range of 10--12 weeks. The *Mertk^−/−^* strain was generated as described previously ([@B27]). All lines were backcrossed for \>9 generations to a C57BL/6 background. Male *Mertk^−/−^* mice and wild-type (WT) littermates at 10 weeks of age were used for CIA and KRN STA experiments and housed in individually ventilated cages. Male and female mice on a C57BL/6 background were used for bone marrow isolations. All mice were fed a standard diet with freely available food and water. Mice which received a treatment (adenovirus or antibody) were randomly allocated to experimental groups. Histological and immunohistochemical analyses were performed in a randomized and blinded manner. Clinical signs of arthritis in paws and ankle joints were monitored macroscopically three times per week. Cumulative scoring was based on redness, swelling, and, in later stages, ankylosis, with a maximal score of 2 per paw. Humane endpoint was defined as reaching an individual score higher than 6 (on a scale of 0--8), followed by euthanization of the mouse. All *in vivo* studies performed in The Netherlands complied with Dutch legislation and were approved by local authorities for the care and use of animals with related codes of practice. The *in vivo* studies executed in The United States of America were conducted according to guidelines established by the Salk Institutional Animal Care and Use Committee. Group sizes were determined by power calculation on basis of incidence, mean, and SD, and are indicated per experiment.

### KRN STA {#S2-2-2}

KRN STA was induced by two intraperitoneal injections, at day 0 and 2, of 150 µL arthritic K/BxN serum in either WT or *Mertk^−/−^* mice or in WT C57BL/6J mice that virally overexpressed *luciferase* (Ad Luc) or *Pros1* (Ad Pros1) in their knee joints. The overexpression of *luciferase* or *Pros1* was accomplished by an intra-articular injection into the knee joint of 1 × 10^7^ plaque-forming units (PFU) of adenovirus, 24 h prior to the first serum injection. Mice were euthanized at day 7 or 14, respectively.

### Collagen-Induced Arthritis {#S2-2-3}

For induction of CIA in DBA/1 mice, bovine type II collagen was dissolved in 0.05 M acetic acid at a concentration of 2 mg/mL and emulsified in an equal volume of Freund's complete adjuvant (2 mg/mL of *Mycobacterium tuberculosis* strain H37Ra; Difco). Mice were immunized with 100 µL of this emulsion intradermally at the base of the tail. At day 21, mice were given an intraperitoneal booster injection of 100 µg of type II collagen dissolved in phosphate-buffered saline (PBS). One day after the booster injection, mice were injected intravenously with 10 µg of anti-MER (AF591) or IgG (AB-108-C) or 3 × 10^8^ PFU of Ad Luc or Ad Pros1. Mice were euthanized at day 30 or day 36, respectively.

*In Vitro*---Human {#S2-3}
------------------

### Patient Material {#S2-3-1}

RA synovial tissue was obtained during surgery from the Radboud University Medical Center or the Sint Maartenskliniek (both the Netherlands). This material was considered surgery surplus material. For the Radboud University Medical Center, patients gave informed consent for the surgery, were informed and were able to decline the use of their material for research. According to Dutch law, informed consent was not necessary. In addition, patient material was anonymized. For the Sint Maartenskliniek, patients gave written informed consent for the use of their material for research. The patient material was pseudonymized. Therefore, there was no need for the approval by an ethical committee. Protocols were performed in accordance to the code of conduct for responsible use of human tissue in medical research (Gedragscode 2011, <https://www.federa.org/code-goed-gebruik>). Synovial samples were digested using Liberase TM (50 µg/mL; Roche) for 2 h at 37°C in Roswell Park Memorial Institute (RPMI) medium (Gibco). Subsequently, red blood cells were lysed. Cells were put in culture with RPMI medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 1 mM pyruvate and penicillin/streptomycin (P/S). Medium was refreshed weekly. Cells were kept at 37°C with 5% CO~2~.

### Human Monocytes {#S2-3-2}

Whole blood from healthy donors was mixed with PBS 1.5% acid citrate-dextrose solution A 1:1. Peripheral blood mononuclear cells were isolated by a density gradient centrifugation method using Ficoll-Paque PLUS (GE Healthcare). CD14^+^ cells were isolated with the MagniSort Human CD14 Positive Selection Kit according to manufacturer's protocol (Invitrogen) (purity \>90%).

### Human Synovial Three-Dimensional Micromasses {#S2-3-3}

For the construction of micromasses, rheumatoid arthritis fibroblast-like synoviocytes (RAFLS) obtained from synovial samples (see [Patient Material](#S2-3-1){ref-type="sec"}) and monocytes were mixed with a ratio of 1:5 (200.000 RAFLS and 1 × 10^6^ monocytes per micromass). The cell suspension was centrifuged and cell pellets were dissolved in ice-cold Matrigel (Corning). Using cooled pipette tips, 25 µL droplets were placed in 24-well culture plates which were coated with poly-(2-hydroxyethyl methacrylate) (Sigma-Aldrich). After 30 min gelation at 37°C, RPMI medium supplemented with 10% FCS, 1 mM pyruvate and P/S was added. Micromasses were kept at 37°C with 5% CO~2~. After 7 days of culture, the formation of a synovial-like lining was confirmed on histology (not shown). Subsequently, experiments were set in. In one set of experiments, micromasses were pre-incubated with 50 nM PROS1 (Haematologic Technologies) for 24 h before stimulation with 100 ng/mL *E. coli* lipopolysaccharide (LPS) (Invivogen), 100 ng/mL Pam3Cys-Ser(Lys)4 (P3C) (Invivogen) or 10 ng/mL recombinant human TNF-α (Abcam). After 6 h, cells were lysed in TRIzol (Sigma-Aldrich) and processed for quantitative PCR analysis. Supernatants were collected after 24 h for further analysis. In another set of experiments, micromasses were treated with human anti-MER \[Abcam; as previously described ([@B28])\]. Supernatants were collected after 24 h for further analysis.

*In vitro*---Murine {#S2-4}
-------------------

### *In Vitro Pros1* Overexpression {#S2-4-1}

Bone marrow cells were isolated by flushing murine femur and tibia bones followed by red blood cell lysis. Cells were differentiated into bone marrow-derived macrophages (BMMs) by culturing them in the presence of 15 ng/mL M-CSF (R&D). Medium was refreshed at day 4. At day 7, BMMs were transduced with adenoviruses encoding for *luciferase* or *Pros1* with a multiplicity of infection of 200. Viruses were removed after 2 h. After 48 h, cells were stimulated with 100 ng/mL LPS or 100 ng/mL P3C. After 6 h, cells were lysed in TRIzol and processed for quantitative PCR analysis. Supernatants were collected after 24 h for further analysis.

### Cell Lines {#S2-4-2}

J774A.1 macrophages were maintained in Dulbecco's modified eagle medium (Life Technologies). EL-4 T cells were cultured in RPMI medium. Both media were supplemented with 10% FCS, 1 mM pyruvate and P/S. Cells were kept at 37°C with 5% CO~2~.

### Apoptosis Induction {#S2-4-3}

EL-4 cells were serum-starved for 16 h and incubated with 2 µM Staurosporine for 4 h. This resulted in 70% apoptotic cells verified by Annexin V and 7-AAD staining and flow cytometry, measured on FACSCalibur (BD Biosciences).

### *In Vitro* Efferocytosis Assay {#S2-4-4}

J774A.1 cells were cultured on eight-well chamber slides, serum-starved for 16 h, and pre-incubated with anti-MER or IgG for 30 min. Apoptotic cells were labeled with pHrodo (Life Technologies) as described previously ([@B29]). J774A.1 cells were co-incubated with a 10-fold excess of apoptotic cells in presence of anti-MER or IgG for 2 h. Excess of apoptotic cells was removed and J774A.1 cells were fixed with 4% paraformaldehyde (PFA). Slides were incubated with rat anti-mouse F4/80 (Bio-Rad) followed by AF488-labeled goat anti-rat IgG (Invitrogen). Nuclei were stained with DAPI. Pictures were taken and the ratio of phagocytic macrophages compared to total number of macrophages was determined per well. Cells were counted as phagocytic if there was at least one pHrodo-labeled apoptotic cell within the F4/80-labeled membrane. The quantification was performed in a randomized and blinded manner by two independent observers.

### *In Vitro* Secondary Necrosis Assay {#S2-4-5}

J774A.1 cells were cultured on eight-well chamber slides. Bone marrow neutrophils were isolated using Anti-Ly-6B.2 (7/4) Micro-Beads (Miltenyi Biotec) according to manufacturer's protocol after flushing tibia and femur bones and red blood cell lysis. Neutrophils were cocultured with J774A.1 cells at a ratio 2:1 in the presence of 5 µg/mL anti-MER or IgG for 24 or 48 h. For microscopy, cells were stained with F4/80 and DAPI as described for "*in vitro* efferocytosis assay" and representative pictures were taken. Supernatants after 48 h coculture were collected for further analysis.

Other {#S2-5}
-----

### Adenoviruses {#S2-5-1}

First generation adenoviruses encoding for *luciferase* (Ad Luc) and *Pros1* (Ad Pros1) were produced as previously described ([@B16]).

### Flow Cytometry MER {#S2-5-2}

Bone marrow-derived macrophages were incubated with mouse Fc Block (BD Pharmingen) to block Fcγ receptors, diluted in FACS buffer \[PBS, 5% FCS, 2 mM ethylenediaminetetraacetic acid (EDTA)\]. Subsequently, surface marker expression was evaluated using rat anti-mouse MER PE (eBioscience). Samples were measured on BD FACSCalibur (BD Biosciences) and analyzed with FlowJo software (Tree Star).

### Histological and Immunohistochemical Analysis {#S2-5-3}

Micromasses at day 7 of culture were fixed for 2 h in 2% PFA in PBS/1 mM CaCl~2~, dehydrated, and embedded in paraffin. Sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin to confirm synovial-like lining formation or were further processes for immunohistochemistry. Knee joints were fixed in formalin, decalcified with formic acid, and embedded in paraffin. Tissue sections were stained with safranin O and fast green (both BHD Chemicals) or were further processed for immunohistochemistry. Three semi-serial sections per joint were scored for histopathologic changes on an arbitrary scale from 0 to 3, by two independent observers in a blinded manner as described previously ([@B30]). The average of the three semi-serial sections is depicted per joint. Joint inflammation was determined by the presence of synovial cell infiltrates and inflammatory cell exudates. Connective tissue destruction was determined by the depletion of proteoglycans and by cartilage and bone erosion. CD 68 and MER were evaluated on paraffin section of micromasses. Cleaved Caspase-3 was evaluated on paraffin sections of murine knee joints. Sections were deparaffinized and rehydrated. Antigen-retrieval was performed in Tris/EDTA buffer at 60°C for MER and citrate buffer at 60°C for CD68 and cleaved Caspase-3. Endogenous peroxidase was blocked by 3% hydrogen peroxide. Tissue sections were incubated with 0.2 µg/mL rabbit anti-human MER (Abcam) or control rabbit IgG followed by incubation with biotinylated goat anti-rabbit (Vector Labortatories), 41 µg/mL mouse anti-human CD68 (DAKO), or control mouse IgG, followed by rabbit anti-mouse horseradisch peroxidase-labeled antibody (DAKO), or 0.5 µg/mL rabbit anti-cleaved Caspase-3 (BD Bioscience) or control rabbit IgG followed by incubation with biotinylated goat anti-rabbit (Vector Labortatories). A biotin--streptavidin detection system was used according to manufacturer's protocol for MER and cleaved Caspase-3 (Vector Laboratories). Bound complexes were visualized *via* reaction with diaminobenzidine (Sigma-Aldrich). All sections were counterstained with hematoxylin. For cleaved Caspase-3, two to six pictures were taken of different areas of each joint section in a standardized and blinded manner. Three semi-serial tissues sections per joint were analyzed. The average of the three semi-serial sections was depicted per joint. Quantification of the staining was performed using the LAS V4.3 software (Leica). The inflamed area was selected and the area of cleaved Caspase-3 positive cells was expressed as percentage.

### RNA Isolation and Quantitative PCR Analysis {#S2-5-4}

3-mm synovial biopsies were disrupted using the MagNA Lyser (Roche). Biopsies, BMMs and micromasses were lysed with TRIzol. Total RNA was extracted using TRIzol/Chloroform extraction and treated with DNAse followed by reverse transcription into cDNA using oligo(dT) primers. Quantitative PCR was performed with SYBR green PCR master mix using the StepOnePlus Real-Time PCR System (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (*Gapdh* or *GAPDH*) was used as reference gene. The primer sequences are listed in Table [2](#T2){ref-type="table"}. The C~T~ value was set to a threshold of 40 in the samples in which no C~T~ value was detected.

###### 

List of oligonucleotide primer sequences.

  Species   Oligo description   Sequence (5′ → 3′)
  --------- ------------------- -----------------------------
  Human     GAPDH_FW            ATCTTCTTTTGCGTCGCCAG
  Human     GAPDH_RV            TTCCCCATGGTGTCTGAGC
  Human     IL1B_FW             TGGGTAATTTTTGGGATCTACACTCT
  Human     IL1B_RV             AATCTGTACCTGTCCTGCGTGTT
  Human     TNF_FW              TCTTCTCGAACCCCGAGTGA
  Human     TNF_RV              CCTCTGATGGCACCACCAG
  Human     ADAM17_FW           TCACGTTTGCAGTCTCCAAA
  Human     ADAM17_RV           CACTCGATGAACAAGCTCTTC
  Human     PROS1_FW            CCCTGGAGGTTACACTTGCT
  Human     PROS1_RV            ACTGCTCCGCCAAGTAAAGT
  Mouse     Gapdh_FW            GGCAAATTCAACGGCACA
  Mouse     Gapdh_RV            GTTAGTGGGGTCTCGCTCCTG
  Mouse     Il1b_FW             GGACAGAATATCAACCAACAAGTGATA
  Mouse     Il1b_RV             GTGTGCCGTCTTTCATTACACAG
  Mouse     Tnf_FW              CAGACCCTCACACTCAGATCATCT
  Mouse     Tnf_RV              CCTCCACTTGGTGGTTTGCTA
  Mouse     Ccl2_FW             TTGGCTCAGCCAGATGCA
  Mouse     Ccl2_RV             CCTACTCATTGGGATCATCTTGCT
  Mouse     Ccl3_FW             TTGGCTCAGCCAGATGCA
  Mouse     Ccl3_RV             CCTACTCATTGGGATCATCTTGCT
  Mouse     Mmp3_FW             TGAAGCCACCAACATCAGGA
  Mouse     Mmp3_RV             TGGAGCTGATGCATAAGCCC
  Mouse     Mmp13_FW            AGACCTTGTGTTTGCAGAGCACTAC
  Mouse     Mmp13_RV            CTTCAGGATTCCCGCAAGAG
  Mouse     Mmp14_FW            GCCTGCATCCATCAAACT
  Mouse     Mmp14_RV            CAGTGCTTATCTCCTTTGAAGAAG
  Mouse     Il17a_FW            CAGGACGCGCAAACATGA
  Mouse     Il17a_RV            GCAACAGCATCAGAGACACAGAT
  Mouse     Il6_FW              CAAGTCGGAGGCTTAATTACACATG
  Mouse     Il6_RV              ATTGCCATTGCACAACTCTTTTCT
  Mouse     Cxcl1_FW            TGGCTGGGATTCACCTCAA
  Mouse     Cxcl1_RV            GAGTGTGGCTATGACTTCGGTTT
  Mouse     Mmp9_FW             GGAACTCACACGACATCTTCCA
  Mouse     Mmp9_RV             GAAACTCACACGCCAGAAGAATTT
  Mouse     Socs1_FW            CCGTGGGTCGCGAGAAC
  Mouse     Socs1_RV            AAGGAACTCAGGTAGTCACGGAGTA
  Mouse     Socs3_FW            TAGACTTCACGGCTGCCAAC
  Mouse     Socs3_RV            CGGGGAGCTAGTCCCGAA
  Mouse     Pros1_FW            GCACAGTGCCCTTTGCCT
  Mouse     Pros1_RV            CAAATACCACAATATCCTGAGACGTT
  Mouse     Adam17_FW           ATCGTTGGGTCTGTTCTGGTT
  Mouse     Adam17_RV           ATCTCAATGTTACTGTGATGAAACA

### Measurement of Cytokines and Chemokines {#S2-5-5}

Cytokines and chemokines in sera and supernatants were measured on a Bio-Plex 200 system using a magnetic bead-based multiplex immunoassay. Data analysis was performed with Bio-Plex Manager software (all Bio-Rad). IL-16C in sera and super-natants was examined using the mouse IL-16 DuoSet ELISA (DY1727; R&D systems). Murine soluble MER in sera and supernatants was examined using the mouse MER DuoSet ELISA (DY591; R&D systems). Human soluble MER in supernatants was examined using the total human MER DuoSet ELISA (DYC891; R&D systems). All ELISAs of R&D systems were used according to manufacturer's instructions using the DuoSet Ancillary Reagent kit 2 (DY008; R&D systems).

### Immunoprecipitation and Immunoblotting {#S2-5-6}

Tissues were snap frozen in liquid nitrogen and processed for immunoprecipitation and immunoblotting as described previously ([@B31]). Tissues lysed on ice in lysis buffer. Cell lysates were incubated overnight at 4°C with protein-G/A Sepharose to pre-clear lysates. For immunopreciptation (IP), cell lysates were incubated for 2.5 h at 4°C with anti-Mer. Protein G-Sepharose (Invitrogen) was added for 2 h and immunoprecipitates (IPs) were washed twice with lysis buffer containing 0.5 M NaCl and once with 50 mM Tris/HCl pH 7.5. IPs were eluted in SDS sample buffer, separated on polyacrylamide gels, and transferred to PVDF membranes. Membranes were blocked in TBST containing 5% bovine serum albumin and immunoblotted overnight at 4°C with primary antibodies diluted 1:1,000 in blocking buffer. Blots were then washed in TBST and incubated for 1 h at RT with secondary HRP-conjugated antibodies (GE Healthcare) diluted 1:5,000 in 5% skim milk in TBST. After repeating the washes, signal was detected with enhanced chemiluminescence reagent.

Statistics {#S2-6}
----------

Data are depicted as dot-plots, dot-plots with mean, mean + SD, or mean + SEM, as indicated per figure. Analysis of significance was performed using a two-tailed paired or unpaired *t*-test as indicated per experiment when comparing two groups. One-way ANOVA with Bonferroni's multiple comparison test was used if more than two groups were compared. All data were analyzed with GraphPad Prism 5. Number of samples is depicted per experiment in figure legends. *p*-Values equal to or lower than 0.05 were considered to be statistically significant.

Results {#S3}
=======

Genetic Ablation of *Mertk* Results in Enhanced Arthritis Severity, Both Clinically and Histologically {#S3-1}
------------------------------------------------------------------------------------------------------

Naive *Mertk^−/−^* mice did not develop arthritis spontaneously in their knee joints and these knee joints were indistinguishable from WT knee joints (Figure [1](#F1){ref-type="fig"}A). KRN STA was induced and 7 days later, more severe joint inflammation both clinically (Figure [1](#F1){ref-type="fig"}B) as well as histologically (Figures [1](#F1){ref-type="fig"}A,C) in *Mertk^−/−^* as compared to WT mice was observed. In addition, knee joints of *Mertk^−/−^* demonstrated more cartilage proteoglycan depletion, and cartilage and bone erosion than WT mice (Figures [1](#F1){ref-type="fig"}A,C).

![Effect of genetic ablation of *Mertk* on naive and arthritic knee joints with KRN serum transfer arthritis (STA). **(A)** Naive (*n* = 6 mice) or arthritic (KRN STA) wild-type (WT) and *Mertk^−/−^* mice (*n* = 9--15 mice) were euthanized at day 7. Shown are representative pictures of histological knee joint sections stained with safranin O and fast green. **(B)** Macroscopic score of knee joints of arthritic mice as determined by swelling and blood vessel formation (*n* = 18--30 knee joints). **(C)** Histological knee joint sections of arthritic mice were scored for the arthritis parameters depicted. Three semi-serial sections per joint were scored in a random and blinded manner with an arbitrary score from 0 to 3 (*n* = 10--18 knee joints). P, patella; F, femur; S, synovium. For **(B,C)**, data are represented as mean + SEM. \**p* \< 0.05, \*\**p* \< 0.01 with unpaired *t*-test.](fimmu-09-00742-g001){#F1}

Adenoviral Overexpression of *Pros1* Reduces Inflammatory and Destructive Mediators and Arthritis Pathology {#S3-2}
-----------------------------------------------------------------------------------------------------------

*Mertk* deficiency showed an endogenous protective role of MER during arthritis. Therefore, next, we tested whether MER activation by PROS1 could further enhance this protection. Murine BMMs were transduced with an adenovirus overexpressing *Luciferase* (Ad Luc) or *Pros1* (Ad Pros1) 48 h prior to activation of TLR4 and TLR2. BMMs expressed prominent levels of MER and adenoviral overexpression of *Pros1* resulted in enhanced expression of *Pros1* (Figures [S1](#SM1){ref-type="supplementary-material"}A,B in Supplementary Material). *Pros1* overexpression almost completely abolished the LPS- and P3C-induced gene and protein expression of IL-1β and TNF-α (Figure [2](#F2){ref-type="fig"}A). In addition, CCL2 protein, but not mRNA levels, were significantly reduced by Ad Pros1 (Figure [2](#F2){ref-type="fig"}A). Moreover, *Adam17* expression and soluble MER levels were significantly reduced by Ad Pros1 (Figures [S1](#SM1){ref-type="supplementary-material"}C,D in Supplementary Material). This confirmed the anti-inflammatory capacity of Ad Pros1. Next, the effect of adenoviral overexpression of *Pros1* in knee joints of mice with KRN STA was examined. In line with the *in vitro* results of *Pros1* overexpression, reduced expression of *Il1b, Tnf*, and *Ccl2* was detected in synovium of mice treated with Ad Pros1 compared to Ad Luc (Figure [2](#F2){ref-type="fig"}B). Histology taken at day 14 of KRN STA showed a significant reduction of proteoglycan depletion and cartilage erosion in the knee joints of *Pros1*-overexpressing mice (Figures [2](#F2){ref-type="fig"}C,D). In addition, both bone erosion and the amount of cells infiltrating into the synovium were reduced in mice overexpressing *Pros1* (Figures [2](#F2){ref-type="fig"}C,D). Consistent with the reduction of cartilage erosion, overexpression of *Pros1* resulted in significantly diminished expression levels of multiple matrix metalloproteinases (MMPs) in the synovium (Figure [S2](#SM2){ref-type="supplementary-material"}A in Supplementary Material). In constrast to the *in vitro* data, Ad Pros1 did not affect synovial *Adam 17* expression nor the serum concentration of soluble MER (Figures [S2](#SM2){ref-type="supplementary-material"}B,C in Supplementary Material).

![Outcome on inflammation and arthritis pathology following adenovirally overexpressing *Pros1* in KRN serum transfer arthritis (STA). **(A)** Bone marrow-derived macrophages were transduced with Ad Luc or Ad Pros1 and stimulated with lipopolysaccharide (LPS) or P3C for 6 (top) or 24 h (bottom). Messenger RNA was extracted and gene expression was determined (top). Supernatants were analyzed (bottom). Data are representative for two independent experiments (*n* = 3 per experiment). **(B)** KRN STA was induced in mice intra-articularly injected with Ad Luc or Ad Pros1 (*n* = 9 mice). Knee synovial biopsies were obtained, mRNA was extracted and gene expression was determined (*n* = 6 knee synovial biopsies). **(C)** Shown are representative pictures of knee joint sections stained with safranin O and fast green. **(D)** Histological knee joint sections were scored for the arthritis parameters depicted. Three semi-serial sections per joint were scored in a random and blinded manner with an arbitrary score from 0 to 3 (*n* = 12 knee joints). P, patella; F, femur; S, synovium; JC, joint cavity. For **(A)**, data are presented as dot-plots with mean. For **(B--D)**, data are represented as mean + SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 with unpaired *t*-test. See also Figures [S1](#SM1){ref-type="supplementary-material"} and [S2](#SM2){ref-type="supplementary-material"} in Supplementary Material.](fimmu-09-00742-g002){#F2}

MER-PROS1 Targeting Modifies the Inflammatory Cytokine Production by Human Three-Dimensional Synovial Micromasses {#S3-3}
-----------------------------------------------------------------------------------------------------------------

Next, we tested whether MER also mediated an anti-inflammatory response in three-dimensional synovial micromasses consisting out of RAFLS and primary macrophages, a standardized model for the human synovium mimicking the synovial hyperplasia and inflammatory responses observed in RA synovium \[manuscript in preparation and published in Ref. ([@B32], [@B33])\]. After 7 days, a lining was formed and immunohistochemistry demonstrated MER^+^ cells dispersed throughout the micromass that had the same morphology as CD68^+^ macrophages (Figure [3](#F3){ref-type="fig"}A). Without any further stimulation, blocking MER by the addition of MER-specific antibodies significantly enhanced the secretion of TNF-α and IL-1β by human synovial micromasses (Figure [3](#F3){ref-type="fig"}B). Conversely, addition of PROS1 significantly reduced the gene expression and protein secretion of TNF-α and IL-1β upon stimulation with several TLR ligands or TNF-α (Figures [3](#F3){ref-type="fig"}C,D). None of the conditions influenced the expression of *ADAM17* or the shedding of MER (Figure [S3](#SM3){ref-type="supplementary-material"} in Supplementary Material). This showed that MER exerted an anti-inflammatory effect under naive conditions that could be further enhanced by the addition of PROS1.

![Production of pro-inflammatory cytokines by three-dimensional synovial micromasses after anti-MER or PROS1 treatment. **(A)** Micromasses were examined for their protein expression of MER and CD68 (macrophage marker). Shown are representative pictures and IgG controls. **(B)** Micromasses were treated with IgG or anti-MER for 24 h. Supernatants were examined for the presence of tumor necrosis factor alpha (TNF-α) and IL-1β (*n* = 4). **(C)** Micromasses were preincubated with 50 nM Pros1 for 24 h and stimulated with lipopolysaccharide (LPS) (100 ng/mL), P3C (100 ng/mL), or TNF-α (10 ng/mL) for 6 h. Messenger RNA was extracted and gene expression was determined (*n* = 3). **(D)** Micromasses were pre-incubated with 50 nM Pros1 for 24 h and stimulated with LPS (100 ng/mL), P3C (100 ng/mL), or TNF-α (10 ng/mL) for 24 h. Supernatants were analyzed (*n* = 3). All data are representative for two independent experiments. For **(B--D)**, data are presented as dot-plots with mean. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 with unpaired *t*-test. See also Figure [S3](#SM3){ref-type="supplementary-material"} in Supplementary Material.](fimmu-09-00742-g003){#F3}

MER-Specific Antibodies Aggravate Arthritis Pathology {#S3-4}
-----------------------------------------------------

Treatment of RA patients with PROS1 will not be the first choice because the majority of PROS1 complexes with C4b-binding protein making it inactive and it only has a half-life of approximately 2 days ([@B34]--[@B37]). Moreover, free PROS1 contains potent anti-coagulation activity ([@B38]). A more efficient and safer approach would be the use of MER-specific antibodies that were previously described to activate MER kinase activity ([@B21], [@B31]). We tested this approach in the CIA model. Anti-MER or IgG was administered intravenously at day 22 of CIA and this led to MER phosphorylation in lung and to a lesser extent liver 1 h thereafter (Figure [4](#F4){ref-type="fig"}A). Unexpectedly, anti-MER treatment markedly increased arthritis severity, determined by macroscopic knee swelling and blood vessel formation at day 30 of CIA (Figure [4](#F4){ref-type="fig"}B). Moreover, histology of knee joints showed that the anti-MER treatment resulted in a trend toward more infiltrating cells in the synovial lining (infiltrate) and significant higher amount of cells in the joint cavity (exudate). Furthermore, higher cartilage depletion, and cartilage and bone erosion were observed after administration of anti-MER (Figures [4](#F4){ref-type="fig"}C,D). To determine the effect of anti-MER on the local expression of cytokines and MMPs, gene expression analysis of synovium was performed. Consistent with the increased bone destruction, enhanced expression of *Il17a* was observed in synovium of mice that received anti-MER. A trend of enhanced expression of *Il6* and *Cxcl1* in synovium and IL-6 and KC protein levels in sera was observed after anti-MER treatment (Figures [S4](#SM4){ref-type="supplementary-material"}A,B in Supplementary Material). Moreover, anti-MER significantly enhanced *Mmp9* and *Mmp13* expression in the synovium, consistent with increased cartilage erosion (Figure [S4](#SM4){ref-type="supplementary-material"}C in Supplementary Material). The enhanced synovial *Socs3* expression could be an indication that the MER-specific antibodies evoked a local anti-inflammatory response (Figure [S4](#SM4){ref-type="supplementary-material"}D in Supplementary Material), but if so, it appeared to be overruled during arthritis. Anti-MER did neither induce shedding of soluble MER in the serum nor did it alter *Adam17* expression (Figures [S4](#SM4){ref-type="supplementary-material"}E,F in Supplementary Material).

![Effect of MER-specific antibody treatment on clinical severity and pathology of collagen-induced arthritis (CIA). **(A)** Mice with CIA were intravenously injected with IgG or anti-MER (*n* = 11--12 mice). Two mice were euthanized 1 h after injection. Lung, liver, and spleen were isolated and samples were immunoprecipitated (IP) for MER and immunoblotted for MER or phosphorylation (pY) (*n* = 1). **(B)** Macroscopic score of knee joints as determined by swelling and blood vessel formation (*n* = 20--22 knee joints). **(C)** Shown are representative pictures of histological knee joint sections stained with safranin O and fast green of each group. **(D)** Histological knee joint sections were scored for the arthritis parameters depicted. Three semi-serial sections per joint were scored in a random and blinded manner with an arbitrary score from 0 to 3 (*n* = 20--22 knee joints). P, patella; F, femur; S, synovium; JC, joint cavity. For **(B--D)**, data are presented as mean + SEM. \**p* \< 0.05, \*\**p* \< 0.01 with unpaired *t*-test. See also Figure [S4](#SM4){ref-type="supplementary-material"} in Supplementary Material.](fimmu-09-00742-g004){#F4}

MER Mediates Efferocytosis in the Arthritic Knee Joint {#S3-5}
------------------------------------------------------

Administration of MER-specific antibodies in mice with CIA enhanced the joint inflammation and more apoptotic cells were present as detected by immunohistochemical staining of cleaved Caspas-3 (Figure [5](#F5){ref-type="fig"}A), a marker for apoptotic cells ([@B7]). Quantitative image analysis showed that the cleaved Caspase-3 positive area within the inflamed area was increased by anti-MER treatment (Figure [5](#F5){ref-type="fig"}B). This suggests that the MER-specific antibodies could have negatively influenced efferocytosis during arthritis in the knee joint. In agreement with this, anti-MER reduced the efferocytosis of apoptotic cells by J774A.1 macrophages in a dose-dependent manner (Figure [S5](#SM5){ref-type="supplementary-material"}A in Supplementary Material). To confirm the role of MER in efferocytosis during arthritis, knee joint sections from previous *in vivo* experiments were stained for cleaved Caspase-3 and quantified. In line with the results of the anti-MER experiments, more apoptotic cells in the knee joints of *Mertk^−/−^* mice with KRN STA were detected (Figure [5](#F5){ref-type="fig"}C). Systemic adenoviral overexpression of the MER ligand PROS1 showed less apoptotic cells in the KNR STA model (Figure [5](#F5){ref-type="fig"}D) and CIA model (Figure [5](#F5){ref-type="fig"}E), indicating efferocytosis was enhanced by *Pros1* overexpression. Altogether, these results show that MER is involved in efferocytosis in the arthritic knee joint and that MER-specific antibodies inhibited this process.

![Evaluating the outcome on efferocytosis after treatment with MER-specific antibodies, *Mertk* gene ablation or *Pros1* overexpression. **(A)** Immunohistochemical staining for cleaved Caspase-3 in knee joints of collagen-induced arthritis (CIA) mice injected with IgG or anti-MER. Shown are representative pictures of knee joint sections with similar microscopic scores of inflammation, in two different magnifications. **(B)** Pictures of knee joint sections shown in **(A)** were quantified and the cleaved Caspase-3 positive area was corrected by the total inflamed area (*n* = 10--12 knee joints). **(C)** Quantification of immunohistochemical staining for cleaved Caspase-3 in knee joints of wild-type (WT) or *Mertk^−/−^* mice with KRN serum transfer arthritis (STA) mice (*n* = 10--18 knee joints). **(D)** Quantification of immunohistochemical staining for cleaved Caspase-3 in knee joints of CIA mice intravenously injected with Ad Luc or Ad Pros1 (*n* = 18 knee joints). **(E)** Quantification of immunohistochemical staining for cleaved Caspase-3 in knee joints of KRN STA mice intra-articularly injected with Ad Luc or Ad Pros1 (*n* = 12 knee joints). P, patella; F, femur; S, synovium. For **(B--E)**, data are presented as mean + SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 with unpaired *t*-test. See also Figure [S5](#SM5){ref-type="supplementary-material"} in Supplementary Material.](fimmu-09-00742-g005){#F5}

MER-Mediated Efferocytosis Limits the Secondary Necrosis of Apoptotic Cells in the Arthritic Joint {#S3-6}
--------------------------------------------------------------------------------------------------

Effective clearance of apoptotic cells by efferocytosis is essential for tissue homeostasis. If this process is impaired, apoptotic cells go into a process of secondary necrosis ([@B39], [@B40]). When neutrophils go into secondary necrosis, the intracellular inactive pre-IL-16 is cleaved in a Caspase-3-dependent manner to the biologically active IL-16C and released ([@B40]). To show that blocking MER-mediated efferocytosis leads to secondary necrosis, neutrophils were cocultured with macrophages in the presence of anti-MER or IgG. Anti-MER prevented the uptake of apoptotic neutrophils (Figure [6](#F6){ref-type="fig"}A) and culture supernatants showed increased IL-16C (Figure [6](#F6){ref-type="fig"}B) and TNF-α levels (Figure [6](#F6){ref-type="fig"}C). The IL-16C most likely originated from neutrophils, as IL-16C was not detectable in this assay in the absence of neutrophils. In these conditions, TNF-α protein levels and *Adam17* expression were unaltered. However, anti-MER did abolish all soluble MER in the supernatant (Figures [S5](#SM5){ref-type="supplementary-material"}B--D in Supplementary Material). Anti-MER administration led to a significant increase of systemic IL-16C protein levels at day 30 of CIA (Figure [6](#F6){ref-type="fig"}D), suggesting that prevention of efferocytosis by blocking MER led to secondary necrosis of neutrophils in the arthritic joint. In addition, systemic IL-16C levels were significantly higher in *Mertk*-deficient mice (Figure [6](#F6){ref-type="fig"}E). Conversely, systemic levels of IL-16C were significantly reduced in CIA mice treated with Ad Pros1 compared to Ad Luc (Figure [6](#F6){ref-type="fig"}F). This showed that MER plays a protective role during arthritis by mediating efferocytosis and that this nullifies the protective effect of agonistic MER-specific antibodies in arthritis. Blocking of efferocytosis by anti-MER led to a pro-inflammatory cascade initiated by the secondary necrosis of apoptotic neutrophils.

![Assessment of secondary necrosis after treatment with MER-specific antibodies, *Mertk* gene ablation or *Pros1* overexpression. **(A)** J774A.1 cells were incubated with IgG or anti-MER and cocultured with bone marrow neutrophils for 24 h. Cells were stained with F4/80 (green) and DAPI (blue). Representative pictures are shown for each group. White arrows indicate an engulfed cell (IgG group) or an apoptotic cell (anti-MER group). **(B)** J774A.1 cells were incubated with IgG or anti-MER and cocultured with bone marrow neutrophils for 48 h. Supernatants were examined for the presence of interleukin (IL)-16C (*n* = 6 individual experiments). **(C)** Supernatants of **(B)** were analyzed for the presence of tumor necrosis factor alpha (TNF-α) (*n* = 6 individual experiments). **(D)** Serum samples from collagen-induced arthritis (CIA) mice systemically treated with IgG or anti-MER were analyzed for IL-16C (*n* = 10--11 mice). **(E)** Serum samples from wild-type (WT) or *Mertk^−/−^* mice with KRN serum transfer arthritis were analyzed for IL-16C (*n* = 9--15 mice). **(F)** Serum samples from mice with CIA intravenously injected with Ad Luc or Ad Pros1 were analyzed for IL-16C (*n* = 7--8 mice). For **(B,C)**, data are presented as dot-plots. \**p* \< 0.05, \*\**p* \< 0.01 with paired *t*-test. For **(D--F)**, data are presented as mean + SEM. \**p* \< 0.05 with unpaired *t*-test. See also Figure [S5](#SM5){ref-type="supplementary-material"} in Supplementary Material.](fimmu-09-00742-g006){#F6}

Discussion {#S4}
==========

Our study shows that MER plays a protective role during experimental arthritis in the macrophage-dependent KRN STA model ([@B41]), the T and B cell-dependent CIA model ([@B42], [@B43]), and in a three-dimensional model of the human synovium. We found that activating MER by PROS1 is indeed anti-inflammatory and also ameliorates arthritis. However, this could not be mimicked by agonistic MER-specific antibodies, which also possess the bivalent function of blocking MER-mediated efferocytosis.

Mice with a deficiency of *Mertk* showed aggravated diseases and treatment with *Pros1* by viral overexpression ameliorated the disease in the KRN STA model. The latter confirmed our previously published observation of the protective effect of *Pros1* overexpression in the CIA model ([@B16]). MER activation *via* PROS1 delivers a negative feedback signal *via* the induction of SOCS3 that dampens inflammatory cytokine response ([@B10], [@B11], [@B13]--[@B17]). Indeed, we found increased synovial expression of this gene in the CIA model after *Pros1* overexpression ([@B16]). This could explain the arthritis protective effect of MER activation in the mouse models and anti-inflammatory effect of MER activation in the human synovial micromass model. It is also in line with more severe arthritis observed in *Mertk*-deficient mice and higher cytokine release by human synovial micromasses in the presence of blocking MER-specific antibodies. Whether this is all due to SOCS3 induction or through inducing specialized proresolving mediators ([@B21]), remains to be determined.

Based on our results that the endogenous protective role of MER during arthritis could be further enhanced by exogenously delivered PROS1 or viral overexpression, we envision that MER targeting would be a therapeutic option to treat RA patients. However, PROS1 will not be the first choice because this protein has a half-life of only 2 days and its availability is reduced due to complex formation with C4b-binding protein ([@B34]--[@B37]). Local viral delivery of the *Pros1* gene could be an option, but safety is still an issue and an unlikely strategy to treat all affected joints in the RA patient. For that, treatment of RA patients with an agonistic MER-specific antibody would be safer and possibly also more efficient. This was tested in the CIA model and unexpectedly, we found that this specific anti-MER antibody treatment deteriorated the disease due to accumulation of apoptotic cells in the joint that go into secondary necrosis and release their pro-inflammatory content thereby fueling joint inflammation. Although we cannot exclude that anti-MER suboptimally activates the MER receptor, we can conclude that anti-MER interferes with MER-mediated efferocytosis and appears to have a bivalent function: activation of the receptor but also blocking of MER-mediated efferocytosis. It does not appear that the inhibition of efferocytosis is due to shedding of the MER receptor. In all *in vivo* studies, serum levels of soluble MER and *Adam17* expression were unaltered. *In vitro*, anti-MER and adenoviral *Pros1* completely abolished the shedding of MER. The complete absence of soluble MER by MER activation could be due to the internalization of the receptor upon activation, a common method deployed by receptor tyrosine kinases ([@B44]).

The importance of MER in efferocytosis is demonstrated by the fact that adult *Mertk^−/−^* mice exhibit apoptotic cell accumulation in multiple tissues ([@B13], [@B45], [@B46]). During arthritis, neutrophils migrate in high numbers into the joint cavity ([@B47]). Neutrophils are short-lived cells and die by apoptosis ([@B48]). Apoptotic cells which are not taken up by phagocytes undergo secondary necrosis ([@B39], [@B40], [@B49]). We showed that neutrophils (which do not express *Mertk*) went into secondary necrosis when cocultured with anti-MER-treated macrophages, as shown by increased levels of IL-16C. IL-16C is processed from its inactive pre-form in a Caspase-3-dependent manner to the biologically active IL-16C, in neutrophils ([@B40]). Additionally, serum of anti-MER-treated mice and *Mertk^−/−^* mice contained higher levels of IL-16C during arthritis. Conversely, protective effects were observed when *Pros1* was virally overexpressed as IL-16C serum levels were reduced in these mice. IL-16C is a pro-inflammatory cytokine that induces among other IL-6 ([@B50]). We found that the IL-16C levels correlated significantly with the synovial gene expression of *Il6* (*R*^2^ = 0.8349; *p* = 0.0002) in the CIA model. Enhanced levels of IL-16 are observed in RA patients, associated with joint destruction and inflammation, making it tempting to speculate secondary necrosis plays an aggravating role during RA ([@B51], [@B52]). Noteworthy, IL-16 is an extraordinarily effective parameter to measure clinical responses during early treatment ([@B53]).

Little has been described about the TAM receptors and their ligands in human synovium. One study showed that human RA fibroblast-like synoviocytes respond to GAS6, likely *via* TYRO3 and AXL ([@B54]). Another study showed the presence of AXL in human synovial lining cells and also the presence of GAS6 in synovium and synovial fluid ([@B55]). We showed that targeting the MER-PROS1 axis in a human three-dimensional model of the synovium is beneficial both at homeostasis and in an inflammatory environment. Moreover, the cleaved soluble form of MER, present in human synovial fluid of RA patients, impairs efferocytosis (manuscript in preparation).

PROS1 protein therapy and *PROS1* gene therapy are not the first choice for treatment of RA patients whereas the use of antibodies, such as anti-TNF-α, is the first-line biological after methotrexate. However, our study showed that activating the MER receptor using an antibody strategy may have a counterproductive effect of blocking MER-mediated efferocytosis, leading to necrotic cell death that stimulates inflammation. In summary, our data show that MER-mediated efferocytosis plays a crucial role in the arthritis process suggesting that preserving or stimulating this pathway is a therapeutic option in RA.
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###### 

Expression of MER, soluble MER and, Pros1and Adam17 by bone marrow-derived macrophages (BMMs). **(A)** BMMs were analyzed with flow cytometry for the membrane protein expression of MER. Red = unstained, blue = stained for MER. **(B,C)** BMMs were transduced with Ad Luc or Ad Pros1 and stimulated with lipopolysaccharide (LPS) (100 ng/mL) or P3C (100 ng/mL) for 6 h. Messenger RNA was extracted and gene expression was determined (*n* = 3 per experiment). **(D)** BMMs were transduced with Ad Luc or Ad Pros1 and stimulated with LPS (100 ng/mL) or P3C (100 ng/mL) for 24 h. Supernatants were analyzed (*n* = 3 per experiment). For **(B)**, data are presented as dot-plots with mean. For **(C,D)**, data are presented as mean + SEM. \**p* \< 0.01, \*\*\**p* \< 0.001 with unpaired *t*-test comparing Ad Luc to Ad Pros1 conditions. All data are representative for two independent experiments. ND = not detected. See also Figure [2](#F2){ref-type="fig"}.

###### 

Click here for additional data file.

###### 

Effect of local adenoviral Pros1 overexpression on metalloproteinase expression, Adam17 expression and soluble MER levels in KRN STA. KRN STA was induced in mice overexpressing luciferase (Ad Luc) or Pros1 (Ad Pros1) in their knee joints and mice were euthanized at day 14. **(A,B)** Knee synovial biopsies were obtained, mRNA was extracted and gene expression was determined (*n* = 6 knee synovial biopsies). **(C)** Serum samples from the same mice were analyzed for soluble MER (*n* = 12 mice). Data are represented as mean + SEM. \*\**p* \< 0.01, \*\*\**p* \< 0.001 with unpaired *t*-test. See also Figure [2](#F2){ref-type="fig"}.

###### 

Click here for additional data file.

###### 

Expression of Pros1, Adam17, and soluble MER levels by three-24 dimensional synovial micromasses after anti-MER or PROS1 treatment. **(A--C)** Micromasses were treated with IgG or anti-MER for 24 h, mRNA was extracted and gene expression was determined (*n* = 4). (B) Micromasses were treated with IgG or anti-MER for 24 h. Supernatants were examined for the presence of soluble MER (*n* = 4). **(D,E)** Micromasses were preincubated with 50 nM Pros1 for 24 h and stimulated with lipopolysaccharide (LPS) (100 ng/mL), P3C (100 ng/mL) or tumor necrosis factor alpha (TNF-α) (10 ng/mL) for 6 h. Messenger RNA was extracted, and gene expression was determined (*n* = 3). **(F)** Micromasses were pre-incubated with 50 nM Pros1 for 24 h and stimulated with LPS (100 ng/mL), P3C (100 ng/mL) or TNF-α (10 ng/mL) for 24 h. Supernatants were analyzed (*n* = 3). All data are representative for two independent experiments. For **(A--C)**, data are presented as dot-plots with mean. For **(D--F)**, data are presented as mean + SEM. See also Figure [3](#F3){ref-type="fig"}.

###### 

Click here for additional data file.

###### 

Local and systemic effects of anti-MER on inflammation and destruction in collagen-induced arthritis (CIA). Knee synovial biopsies were obtained at day 30 from mice with CIA intravenously injected with 10 µg IgG or anti-MER. Messenger RNA was extracted and gene expression was determined for **(A)** cytokines and chemokines, **(C)** metalloproteinases, or **(D)** SOCS genes and **(E)** Adam17 (*n* = 10 knee synovial biopsies). **(B,F)** Serum samples from the same mice were analyzed for IL-6 and KC by Bio-Plex Multiplex Immunoassay or soluble MER (*n* = 10--11 mice). All data are presented as mean + SEM. \**p* \< 0.05, \*\**p* \< 0.01 with unpaired *t*-test. See also Figure [4](#F4){ref-type="fig"}.

###### 

Click here for additional data file.

###### 

Effect of anti-MER on efferocytosis. **(A)** J774A.1 cells were incubated with IgG or anti-MER and cocultured with pHrodo-labeled apoptotic cells. Efferocytosis was analyzed by fluorescence microscopy (*n* = 6). **(B)** J774A.1 cells were incubated with IgG or anti-MER, mRNA was extracted and gene expression was determined (*n* = 3--4). **(C)** J774A.1 cells were incubated with IgG or anti-MER. Supernatants were examined for the presence of soluble MER (*n* = 4). **(D)** J774A.1 cells were incubated with IgG or anti-MER. Supernatants were examined for the presence of soluble MER (*n* = 4). For **(A)**, data are presented as mean + SD. For **(B--D)**, data are presented as dot-plots with mean. For **(A)**, \*\**p* \< 0.01 with one-way ANOVA with Bonferroni post test. ND, not detected. See also Figure [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}.

###### 

Click here for additional data file.
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